No quarterly revenue total was found in Tevogen Inc.'s SEC filings.
Tevogen Inc. (TVGN) files with the SEC under industry code 2836, Biological Products, (No Diagnostic Substances). As of Jun 30, 2026 it held $1.1 million in cash and investments and $1.4 million in total debt.
Revenue
—
Net income
$-5.76M
-4.7% vs year-ago quarter
Operating cash flow
$-3.01M
+5.8% vs year-ago quarter
Free cash flow
—
EPS
$-1.52
+11.1% vs year-ago quarter
Dividend per share
None
Shares outstanding
6.51M
-96.7% vs year-ago quarter
Net cash
$-309,677
Q2 FY2026
Operating margin
—
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- TVGN (Nasdaq), TVGNW (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Warren, NJ
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1860871
- Former names
- Tevogen Bio Holdings Inc. (until Jul 30, 2026); Semper Paratus Acquisition Corp (until Feb 15, 2024)
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q2 FY2026 Jun 30, 2026 |
Q1 FY2026 Mar 31, 2026 |
Q4 FY2025 Dec 31, 2025 |
Q3 FY2025 Sep 30, 2025 |
Q2 FY2025 Jun 30, 2025 |
|---|---|---|---|---|---|
| Operating income | -$5.7M | -$5.4M | -$4.6M | -$5.7M | -$5.4M |
| Net income | -$5.8M | -$5.4M | -$4.7M | -$5.7M | -$5.5M |
| Diluted EPS | -$1.52 | -$1.61 | $0.01 | -$0.03 | -$1.71 |
| Operating cash flow | -$3.0M | -$2.7M | -$2.2M | -$3.6M | -$3.2M |
| Total assets | $4.7M | $4.9M | $4.4M | $4.5M | $4.3M |
| Total liabilities | $13.6M | $14.8M | $12.6M | $12.3M | $13.8M |
| Stockholders' equity | -$8.9M | -$9.8M | -$8.2M | -$7.8M | -$9.5M |
| Cash and investments | $1.1M | $692,305 | $552,372 | $1.0M | $685,229 |
| Total debt | $1.4M | $1.4M | $1.5M | $1.5M | $1.5M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Officer or director change
|
Nov 4, 2026 | Nov 2, 2026 |
| 8-K |
Current report
Material agreement, New debt, Unregistered share sale, Officer or director change
|
Nov 3, 2026 | Oct 27, 2026 |
| 8-K |
Current report
Other events
|
Sep 30, 2026 | Sep 29, 2026 |
| 8-K |
Current report
Officer or director change
|
Sep 16, 2026 | Sep 14, 2026 |
| 8-K |
Current report
Other events
|
Sep 10, 2026 | Sep 9, 2026 |
| 8-K |
Current report
Officer or director change, Bylaw or fiscal year change, Shareholder vote results
|
Aug 26, 2026 | Aug 24, 2026 |
All 309 Tevogen Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.